Publication:
Prognostic significance of tumor tissue NeuGcGM3 ganglioside expression in patients receiving Racotumomab immunotherapy

Thumbnail Image

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Uskent, Necdet
Ayla, Şule
Özkan, Metin
Teomete, Mehmet
Baloğlu, Hüseyin
Aydinçer, Cenk
Doğan, Ender
Berk, Barkın
Yazar, Aziz

Publication Date

Language

Embargo Status

NO

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Expression of N-glycolyl GM3 (NeuGcGM3) ganglioside was detected in the tumor specimens of patients who were on Racotumomab anti-idiotype vaccine maintenance treatment, and prognostic significance as a biomarker was investigated. No statistically significant association was observed in the multivariate analysis between overall survival and tissue NeuGcGM3 IHC levels. Although numerically there was a difference favoring less intense IHC for better prognosis, this did not reach statistical power. However, there was a strong correlation between Racotumomab doses and overall survival (OS). Mean OS of the patient with more than 10 Racotumomab application was significantly longer than the patient who had less than 10 injections (70.7 months vs. 31.1 months, p<0.001). We propose that, regardless of staining intensity, the presence of NeuGcGM3 in patient tissues might be an indicator of benefit in Racotumomab treatment.

Source

Publisher

Hindawi

Subject

Medicine, Oncology

Citation

Has Part

Source

Journal of Oncology

Book Series Title

Edition

DOI

10.1155/2020/1360431

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

4

Downloads

View PlumX Details